Partner Rohan Virginkar was quoted in “Telia’s No-Monitor FCPA Deal Could Be A Model,” published in Law360, about Swedish telecommunications firm Telia Co. AB’s recent settlement with the federal government over foreign bribery allegations. The nearly $1 billion settlement did not require the company to hire a corporate monitor, a requirement typically seen in other FCPA settlements. Telia did, however, terminate the employment of all personnel directly involved in the alleged misconduct.
Virginkar said the no-monitor aspect of the settlement reflects past Department of Justice pronouncements. “This case is tangible evidence of what the department has been saying for some time: Where a company has taken meaningful steps, the government won’t insist on a monitor,” he said.
Virginkar said the no-monitor aspect of the settlement reflects past Department of Justice pronouncements. “This case is tangible evidence of what the department has been saying for some time: Where a company has taken meaningful steps, the government won’t insist on a monitor,” he said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”